Clearmind Medicine received approval from Yale University’s institutional review board to begin recruiting patients for Parts B and C of its FDA-regulated Phase I/II trial of CMND-100 in healthy volunteers and subjects with Alcohol Use Disorder. The Yale site, led by Anahita Bassir Nia, MD, joins Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center and Hadassah Medical Center as approved recruiting centers. The authorization follows positive Part A results, in which all 24 participants across four ascending-dose cohorts completed treatment as planned, with the study meeting its primary safety and tolerability endpoint and recording no serious adverse events.